The number of people with susceptibility test result for rifampicin in Korea
Korea: The number of people with susceptibility test result for rifampicin was 9,284 in 2021. ▼ Falling
Latest (2021)
9,284
Change on year
down 12.3%
World rank
22nd
of 155 countries
All-time high
13,814
in 2018
All-time low
9,284
in 2021
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Korea, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
Korea recorded 9,284 for the number of people with susceptibility test result for rifampicin in 2021. That is the lowest value across all 5 years on record.
Compared with earlier readings it is down 12.3% on the previous year and down 31.5% over five years.
That places Korea 22nd out of 155 countries with data for 2021, putting it in the top quarter.
The number of people with susceptibility test result for rifampicin in Korea, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 13,558 | — |
| 2018 | 13,814 | +1.9% |
| 2019 | 13,053 | -5.5% |
| 2020 | 10,589 | -18.9% |
| 2021 | 9,284 | -12.3% |
Korea compared with similar countries
- Korea's 9,284 is above the median for high income countries, which is 142, 65.4× the median. (61 countries reporting)
- Korea's 9,284 is above the median for East Asia & Pacific, which is 185, 50.2× the median. (28 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 13,475 | 13,053 | 13,814 | 3 |
| 2020s | 9,936 | 9,284 | 10,589 | 2 |
Countries ranked near Korea
More health data for Korea
- Un projection of annual infant deaths, annual growth rate -1.43 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate 0.1935 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 2,072 deaths per 1,000 people (2090)
- Number of infants who die before age 1 69 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -2.66 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0118 units per person (2025)
- Population ages 00-04, male, annual growth rate -2.76 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Korea?
- The number of people with susceptibility test result for rifampicin in Korea was 9,284 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Korea?
- The highest recorded value was 13,814 in 2018.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Korea?
- The lowest recorded value was 9,284 in 2021.
- How does Korea rank for the number of people with susceptibility test result for rifampicin?
- Korea ranks 22nd out of 155 countries with data for 2021.
- Where does this Korea data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).